Cargando…
Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
INTRODUCTION: Dimethyl fumarate (DMF) showed favorable benefit-risk in patients with relapsing-remitting multiple sclerosis (MS) in phase 3 DEFINE and CONFIRM trials and in the ENDORSE extension study. Disease activity can differ in younger patients with MS compared with the overall population. METH...
Autores principales: | Amezcua, Lilyana, Mao-Draayer, Yang, Vargas, Wendy S., Farber, Rebecca, Schaefer, Sara, Branco, Filipe, England, Sarah M., Belviso, Nicholas, Lewin, James B., Mendoza, Jason P., Shankar, Sai L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195942/ https://www.ncbi.nlm.nih.gov/pubmed/37061656 http://dx.doi.org/10.1007/s40120-023-00475-8 |
Ejemplares similares
-
Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
por: Gold, Ralf, et al.
Publicado: (2020) -
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016) -
Corrigendum to “Safety and Efficacy of Delayed-Release Dimethyl Fumarate in
Patients with Relapsing-Remitting Multiple Sclerosis: 9 Years’ Follow-up of DEFINE,
CONFIRM, and ENDORSE”
Publicado: (2020) -
Long-term safety and efficacy of dimethyl fumarate for up to 13 years
in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study
results
por: Gold, Ralf, et al.
Publicado: (2021) -
Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)